NCT00963768View on ClinicalTrials.gov

A Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of JNJ-28431754 in Patients With Type 2 Diabetes Mellitus

PHASE1CompletedINTERVENTIONAL
Enrollment

116

Participants

Timeline

Start Date

June 30, 2007

Primary Completion Date

December 31, 2007

Study Completion Date

December 31, 2007

Conditions
Diabetes Mellitus, Type 2
Interventions
DRUG

JNJ 28431754

A liquid suspension of 30 mg, 100 mg, 300 mg of JNJ-28431754 taken once (or twice) daily or 600 mg taken once daily will be administered by study personnel directly into the patient's mouth using an oral liquid dispenser for 14 days (Day 1 and Days 3 through 16).

DRUG

Placebo

A liquid suspension of placebo will be administered by study personnel directly into the patient's mouth using an oral liquid dispenser once or twice daily for 14 days (Day 1 and Days 3 through 16).

Trial Locations (3)

Unknown

Chula Vista

Neuss

Seoul

All Listed Sponsors
lead

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

INDUSTRY

NCT00963768 - A Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of JNJ-28431754 in Patients With Type 2 Diabetes Mellitus | Biotech Hunter | Biotech Hunter